What can #TheWhiteLotus teach us about cancer care? 🏝️ Dr. Rahul Banerjee, explores “time toxicity” and why every patient’s journey is unique. How can we better tailor care? Read more: ow.ly/lqjr50VM5zO #Oncology #PatientCare

New study in Blood Advances led by Rahul Banerjee & Gurbakhash Kaur challenges the 8-week driving restriction for patients receiving CAR-T therapy for multiple myeloma (MM). Researchers analyzed 586 patients and found that only 1% experienced driving-relevant adverse events (drAEs) between Weeks 5-8

Rahul Banerjee, MD, (@rahulbanerjeemd.bsky.social) discussed approaches to dosing and tolerability when using talquetamab in patients with relapsed/refractory multiple myeloma. #mmsm | @uwmedicine.bsky.social @fredhutch.bsky.social www.targetedonc.com/view/banerje...

@rahulbanerjeemd.bsky.social @fredhutch.bsky.social @mountsinainyc.bsky.social @mountsinai.bsky.social ashpublications.org/bloodadvance...

Financial Toxicity Is the First Side Effect of Lenalidomide in Multiple Myeloma - Rahul Banerjee @rahulbanerjeemd.bsky.social oncodaily.com/drugs/financ... #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #MM #MultipleMyeloma #Myeloma #Lenalidomide

Median patient-reported hair loss with a scalp cooling device during ASCT for myeloma - Rahul Banerjee @rahulbanerjeemd.bsky.social @cancertherapyadv.bsky.social oncodaily.com/insight/rahu... #Cancer #CancerResearch #HairLoss #Myeloma #BloodCancer #CancerTreatment #Oncology #OncoDaily

My takeaways from RedirecTT-1 (tal/tec dual bsAbs in myeloma #MMsm) for @fredhutch journal watch. [Images but technically no memes in my talk 😉] Efficacy & safety profiles are both striking! I can't help but wonder what earlier IVIG and bsAb de-escalation might have done.

At #ASH24, we caught up with Rakesh Popat to hear the interim results of the ProMMise trial evaluating belantamab + cyclophosphamide & dexamethasone in R/R #Myeloma. Watch here: 👉https://buff.ly/3W3Cgy2 #MMSM #CTSM #TrialUpdate #MultipleMyeloma #HemeSky #HemeOnc @ash-hematology.bsky.social

Very excited to have Prof Tracy King @mmkingt.bsky.social on for a look at the ins and outs of myeloma nursing! She makes a great friendalidomide to anyone navigating this area, wherever you get your podcasts #myeloma #hemesky #meded www.bloodyminded.com.au/allepisodes/...

The PANGEA 2.0 model leverages trajectory data to improve the risk stratification of individuals with #SmolderingMyeloma. Learn more in our recent interview with the lovely Irene Ghobrial: 👉https://buff.ly/49ZYSFl #Myeloma #MMSM #ASH24 #Hematology #HemeSky #HemeOnc @ash-hematology.bsky.social

Happy to share our work published in Nature Medicine! We analyzed 3,066 patients from the French DESCAR-T registry who received #CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%). www.nature.com/articles/s41...

Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study) nej.md/4iZNYTY Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn

Subcutaneous Isatuximab Plus Pd Meets Coprimary End Points, Proves Noninferior to IV Administration in R/R Multiple Myeloma @mayocliniccancer.bsky.social #mmsm #oncology www.onclive.com/view/subcuta...

Dexamethasone dose reductions during multiple myeloma treatment show no difference in survival outcomes, highlighting the need for further research. by Banerjee R, Sexton R (...) Orlowski RZ et 11 al. in Blood #MedSky 📖 read the article:

Two cool #ASH24 abstracts on reducing logistical toxicity for patients: 1. A via @rahulbanerjeemd.bsky.social et al: multi-method real world data to show <1% new-onset CRS/ICANS weeks 5-8-- let people drive! Key for getting to follow up appts after returning home.

Care partners favorite - the “Down with Dex” doctor! @rahulbanerjeemd.bsky.social @ctoddkennedy.bsky.social

Fred Hutch at #ASH24: Catch @rahulbanerjeemd.bsky.social present results of a phase 3 clinical trial of 500 patients demonstrating that 24-hour urine assessments do not add any value or improve prognosis. 👉 bit.ly/49jbaIo

Let’s throw out the jugs! @rahulbanerjeemd.bsky.social presents “24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702” #ASH24

#ASH24 #leusm Heuser: Proposes a reasonable evolution for the meaning of the term MRD. @drchrishourigan.bsky.social @rahulbanerjeemd.bsky.social

Free multiple myeloma response criteria from the pee! Excellent #ASH24 presentation by @rahulbanerjeemd.bsky.social showing that removing 24-hr urine changes response for only 1.1% of 645 patients in the BMT CTN 0702 clinical trial.

Can 24h urine be eliminated as part of IMWG response criteria in myeloma? Secondary analysis of STaMINA by @rahulbanerjeemd.bsky.social at #ASH24 showed that eliminating 24h urine resulted in changed response in 1% with no impact on PFS prediction at any response depth. #hemesky #oncsky #mmsm

What a blast #ASH24 has been!🎥🗞️🩸🇺🇸 Thank you to everyone who has been stopping by our booth 🧡 & BIG thank you to everyone who spoke with us🎙️ Stay tuned as we continue to share our exclusive coverage 👀 👉 vjhemonc.com/event/ash-2024 @ash-hematology.bsky.social @rahulbanerjeemd.bsky.social #HemOnc

Also out in @BloodAdvances during #ASH24 by rising 🌟 @nadineabdal and @MayoMyeloma! PROs strongly correlate with OS in #MMsm. In MVA, fatigue as prognostic for OS as FISH and ASCT 😳 Some confounders (anemia, frailty) but worth studying interventions! ashpublications.org/bloodadvance...

Out in @bloodjournal during #ASH24 - cool work by @freemanlciaraMD @DrFredLocke et al looking at #MMsm CAR-T in myeloma: MTV (by PET-CT), sBCMA, BMPC don't always correlate. Some MTV-high but sBCMA-low pts exist - may not respond durably to BCMA CAR-T. ashpublications.org/blood/articl...

It's really incredible how far things have come.

When I started they all started “We have done thousands of trials in the last 3 decades and none have significant improved survival”, now if we could only stop saying it is incurable. True for the majority but there is a small group that should be acknowledged or at least debated even in IMID/PI era

Almost every review I've ever read about myeloma #MMsm starts with something (true) like, "Recent advances in myeloma have led to significant improvements in..." Quite a jolt to see how different the prognosis was for myeloma 60 years ago... and how these papers used to begin!

Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - @mtmdphd *DRAFT* Table Update: Nov 18, 2024 - cc @grpetersen1 - @HadidiSamer @RahulBanerjeeMD @szusmani et al.

It used to be a Top 10! Every #MyelomaSky KOL on this platform here is cheating except for @rahulbanerjeemd.bsky.social . I can only comment on non-drug related scientific abstracts, so here is my selection from this list plus a few more: 81, 83, 248, 251, 671, 766, 1017, 1019, 1879, 2744 #HemeSky

#mmMRD #mmsm #CARTcell

I've been MRD- for the last 3 yrs. My MM doctor(Dr. Jagannath) said he doubts it will return. Started treatment in 2013. 5+ yrs maintenance(5Mg Rev). Relapsed 2019. Finished all treatments Mar. 2024. IgG Kappa. No SCT.

With my apologies to toddler parents everywhere… “Don’t lose it, reuse it!” Excellent @BloodAdvances work by Goel @MayoMyeloma @VincentRK @myelomaMD et al. Re-using old myeloma #MMsm drugs can work, esp if years out. Very relevant to post-CAR-T! ashpublications.org/bloodadvance...

Excellent open-access #MMsm work in @AjHematology by Zabaleta @BrunoPaiva_UNAV et al! An important footnote for all the CAR-T vs bsAb efficacy debates: when stratified by MRD status, CAR-T and bsAbs do identically. Getting to MRD neg is what matters! onlinelibrary.wiley.com/doi/10.1002/...

This 100x, 24hr urine messes up so many studies as so few actually do it

1/ #ASH24 Choosing my top 10 myeloma abstracts this year was harder than ever!! Kudos to all @ASH_hematology authors for GREAT work 👏 For simplicity, I excluded investigational drugs and focused on: 1️⃣ #MMsm response assessments 2️⃣ Optimizing bsAbs 3️⃣ (Soon) practice-changing

Kicking off the 8th Nursing and Allied Health symposium with our Brazilian nursing colleagues at #IMS2024 Rio! We are in room 204a - come join us

Really excellent multidisciplinary panel in #IMS24 nursing & AHP session @myeloma-society.bsky.social annual meeting on real-world solutions to treatment delivery in #myeloma @rahulbanerjeemd.bsky.social @bethfaiman.bsky.social

Today is the first day of #IMS24. Join us for the President's Address followed by the Keynote. View the program to see the exciting content for the day. rb.gy/b1iu3o

Welcome to Riocentro! Please use the information below for Wi-Fi: Wi-Fi Network: IMS Congress Password: imsbrazil

Our brave new world of “quad-eligible” vs “quad-ineligible” in newly diagnosed myeloma regardless of ASCT is here 👏 Plus isa in 1st line as CD38 mAb… great news for #MMsm pts and congrats to IMROZ team! (And BENEFIT, IsKia, GMMG CONCEPT, & more!) www.fda.gov/drugs/resour...

Nurse/AH welcome all to join us @myeloma-society.bsky.social travel safe - c u in Rio! events.jspargo.com/ims24/CUSTOM...

On our way

So happy to have you in Houston at the #IMF #myeloma meeting to kick off!

T-14 days until #IMS24! @rahulbanerjeemd.bsky.social

Oh right, IMS might drive more myeloma peeps to this platform beyond a few others like @adamssperling.bsky.social, for finding myeloma content add the MyelomaSky feed, should pick up anything with myeloma, #myeloma, #mmsm, #smm, #mgus, and a few other tags

1/ And since we can’t tweet during #IMS24, also worth highlighting CEPHEUS as another LBA! D-VRd vs VRd in ASCT-ineligible #MMsm - large PFS benefit with CD38 addition even if no ASCT. Love simplicity of the last line: ASCT decision-making should not dictate induction choice!

Only a matter of time! Now in NEJM: Rapid remission in refractory lupus with teclistamab (BCMA bsAb) x5 wks, including 3rd SUD. Authors astutely note that CD19 CARs also work here... sounds like the #lymsm and #MMsm fields will compete for which of our fields cures lupus 1st! nej.md/3Th6ewX

🚨 AURIGA results in #IMS24 app! After ASCT in #MMsm, 30-mo PFS 83% Dara-R vs 66% R alone. Can’t directly extrapolate to quad induction or MRD- after ASCT, and not powered for PFS… … but as a previously loud cynic of CD38-R maintenance sans RCT data, I am a changed man 🫡

Are you ready for #IMS24?🤩 In just a few weeks, professionals from around the globe will gather to explore the latest in #myeloma research. Don’t be left behind! Whether in Rio de Janeiro or virtually, be part of the experience. Register today! ➡️ rb.gy/1h136x